The effect of Kangfuxin on the quality of gastric ulcer wound healing

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900026682

Enrollment

Unknown

Registered

2019-10-18

Start date

2019-11-01

Completion date

Unknown

Last updated

2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric ulcer

Interventions

Group 2:Anti acid + gastric mucosa protection group+ Kangfuxin Liquid

Group 1:Anti acid + gastric mucosa protection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Signed informed consent with date; 2. Commit to follow the research procedure and cooperate with the implementation of the whole process research; 3. Specified gender or age range; 4. Patients who meet specific disease diagnosis, symptoms and signs and need ESD operation; 5. Meet the specific laboratory inspection results.

Exclusion criteria

Exclusion criteria: 1. Currently using specific drugs not allowed; 2. Equipped with specific devices (such as cardiac pacemaker); 3. Allergy to research intervention; 4. Febrile diseases in a specific time; 5. Treatment with other experimental drugs within a specific time; 6. Have specified diseases or conditions excluded from the study (physical or psychological, physical examination findings).

Design outcomes

Primary

Measure	Time frame
Pathological index + inflammatory factor;	—

Contacts

Public ContactLu Shuliang

Renji Hospital, Shanghai Jiaotong University School of Medicine

13901738685@139.com+86 021 64370045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026